Core Insights - Alphatec Holdings, Inc. (NASDAQ:ATEC) is recognized as one of the top 14 booming stocks to consider for investment at present [1] Financial Performance - Preliminary total revenue for 2025 increased by 25%, expected to be between $763.4 million and $764.4 million, primarily driven by a 26% surge in surgical revenue [2] - The company reaffirmed its full-year guidance for adjusted EBITDA at $91 million and ended the year with a cash balance of $161 million [2] 2026 Outlook - For fiscal 2026, Alphatec projects revenue of $890 million, with 90% expected to be surgical-related [3] - Adjusted EBITDA is anticipated to be around $130 million, and free cash flow for the year is forecasted at approximately $20 million [3] Strategic Developments - On the same day, Alphatec announced a strategic agreement with Theradaptive, Inc. to acquire exclusive distribution rights in the U.S. for Theradaptive's rhBMP-2 solution, OsteoAdapt, enhancing its position in the procedural ecosystem [4] Market Sentiment - Wall Street has a bullish outlook on Alphatec, with a consensus Strong Buy rating and a one-year average share price target of $24.55, indicating an upside of nearly 40% as of January 12 [5]

Market Overview - The S&P 500 has shown significant gains, registering a 16% increase in 2025, following a 24% rise in 2023 and a 23% rise in 2024, totaling approximately 80% over the past three years, marking the strongest three-year performance since a 90% surge from 2019 to 2021 [1][2]. Economic Forecast - A Financial Times survey predicts a 10% gain in the S&P 500 for 2026, with all surveyed banks expecting the index to surpass 7,500 [2]. - Goldman Sachs anticipates a 12% rally in 2026, driven by earnings growth supported by a strong economy and Federal Reserve rate cuts [2][3]. Stock Valuation Insights - Ben Snider from Goldman Sachs highlights that double-digit profit growth and improved productivity from AI position the market for continued bullish trends, although high stock valuations could pose risks if earnings fall short [3][4]. Stock Selection Methodology - The article identifies U.S.-based stocks with market capitalizations of at least $2 billion that have increased by at least 20% over the past three months, further narrowing the list to those with a 50-day moving average above a 200-day moving average [6]. - The final selection includes 14 stocks with the highest average upside potential, based on data as of January 12, 2026, and includes hedge fund holdings as of Q3 2025 for additional investor interest insights [6][7]. Featured Stocks Alphatec Holdings, Inc. (NASDAQ: ATEC) - Projected revenue for 2026 is between $890 million, with 90% expected to be surgical-related, and adjusted EBITDA anticipated at around $130 million [10]. - The company reported a 25% increase in total revenue for 2025, driven by a 26% surge in surgical revenue, and ended the year with a cash balance of $161 million [9]. - Wall Street has a consensus Strong Buy rating with a one-year average share price target of $24.55, indicating an upside of nearly 40% [12]. Terns Pharmaceuticals, Inc. (NASDAQ: TERN) - The stock has surged over 300% in the past three months, with analysts projecting a further 42.31% upside based on a one-year average share price target of $53.75 [16]. - The company received a Buy rating from Truist Financial, with a price target raised to $56 following positive Phase 1 study results for its lead program targeting chronic myeloid leukemia [14][15]. - Mizuho Securities also reiterated an Outperform rating, indicating strong potential for TERN-701 as a leading treatment for CML [15].

Company Overview - Alphatec Holdings, Inc. is a U.S.-based medical technology company that specializes in innovative solutions for spinal surgery, focusing on proprietary platforms and expanding its portfolio to address complex spinal conditions [6]. Insider Trading Activity - Craig E. Hunsaker, EVP of People & Culture at Alphatec Holdings, executed an open-market sale of 32,584 shares valued at $679,050.56 on December 10, 2025, at a price of $20.84 per share [4][5]. - This sale represented 2.53% of Hunsaker's direct ownership at the time, which is slightly below his historical median of 2.79% for sell trades [3]. - The transaction size was significantly below Hunsaker's recent median sale of 60,876 shares, indicating a smaller-than-usual transaction [4][5]. Market Performance - Alphatec's stock has seen a remarkable 116% rise over the last year, outperforming the S&P 500's 15% total return and the 2.8% decline in the State Street SPDR Health Care Equipment ETF [8]. - Despite a solid preliminary report in January 2026, the stock experienced a nearly 22% drop in one day due to a disappointing mid-teens growth projection, and the company remains unprofitable [9]. Strategic Developments - Alphatec recently announced a partnership with Theradaptive, granting it exclusive U.S. rights to commercialize the OsteoAdapt spinal fusion technology, which is still in clinical trials. This partnership could lead to surgeon adoption and revenue growth if successful [9].

Core Viewpoint - Alphatec Spine is focused on delivering long-term differentiated growth in the spine industry, highlighting a strong track record of execution and significant growth opportunities within the sector [1][2]. Group 1: Company Performance - The management team emphasizes a consistent track record of execution over the past eight years, indicating stability and reliability in the company's operations [2][3]. - The company believes it is an opportune time to be involved in the spine market, suggesting favorable market conditions for growth [3]. Group 2: Growth Opportunities - There are substantial growth opportunities within the medical supplies and devices space, particularly in spine-related products and services [2]. - The company is building a strong infrastructure to support its growth initiatives, which is expected to enhance its market position [2].

Summary of Alphatec Conference Call Company Overview - **Company**: Alphatec Spine - **Industry**: Medical Supplies and Devices, specifically focused on spinal surgery Key Points and Arguments Growth and Financial Performance - Alphatec aims for long-term differentiated growth, with a strong track record of execution and significant growth opportunities in the spine market [2][3] - The company finished 2025 with $764 million in revenue, reflecting a 25% growth, and expects to reach $890 million in revenue by 2026, representing a 17% growth [4][6] - Adjusted EBITDA for 2025 was projected at $91 million (12% of revenue), with expectations of $130 million (15% margin) by 2026 [4][6] - The company has committed to becoming a $1 billion revenue company by 2027, with $180 million in Adjusted EBITDA [5] Market Position and Strategy - Alphatec is now the third largest U.S. market share holder in the spine market, with less than 10% market share across the top 10 U.S. markets, indicating significant growth potential [5][24] - The company has focused on creating clinical distinction to compel surgeon adoption, achieving over 20% growth in surgeon adoption this year [7][8] - The strategy includes proceduralization, which emphasizes the assembly of goods for spine surgery rather than selling individual parts [3][11] Innovations and Technology - Alphatec has made significant investments in informatics and procedural tools, including the acquisition of EOS, a full-body imaging system, and the development of SafeOp, a neurophysiology tool [19][13] - The company is focused on integrating informatics into surgical workflows to improve decision-making and outcomes, with plans to launch Valence, a navigation and robotic tool, in 2026 [14][15][19] - The informatics play is seen as a key driver of long-term value, with a focus on capturing data to enhance surgical decision-making [24][20] Market Dynamics and Competition - The company views recent disruptions in the spine market, such as spin-offs from larger med tech companies, as potential tailwinds for growth [40][41] - Alphatec believes its commitment to neurophysiology and sophisticated surgical tools provides a competitive advantage over fast-following competitors [44][46] Future Outlook - The company anticipates continued strong growth driven by surgical volume and adoption, with a target of $100 million in EOS revenue by 2027 [32][25] - Seasonality effects are expected to influence revenue patterns, particularly with the growing presence in pediatric deformity [31][35] - Alphatec is focused on maintaining profitability while investing in R&D and sales channels to support growth [50][51] Conclusion - The financial outlook for Alphatec is positive, with a commitment to achieving $890 million in revenue and $130 million in Adjusted EBITDA by 2026, alongside a focus on innovation and market expansion [29][50]

Core Insights - Alphatec Holdings, Inc. (ATEC) is showing continued growth while reducing losses, which is a positive development for the company [1] - There are concerns regarding persistent losses and ongoing dilution that may affect the company's financial health in the long term [1] Company Analysis - The company has been recognized for its ability to deliver growth, which is a key indicator of its operational performance [1] - Despite the growth, the company is still facing challenges related to financial losses, which could impact investor confidence [1] Investment Opportunities - The analysis suggests that there are actionable ideas related to major corporate events such as earnings reports, mergers, and acquisitions that could present investment opportunities [1] - The service mentioned provides coverage of approximately 10 major events monthly, focusing on identifying the best opportunities for investors [1]

Core Insights - Alphatec Holdings, Inc. (ATEC) has secured exclusive U.S. rights to market and distribute Theradaptive's OsteoAdapt® platform, marking a significant partnership in the spine industry aimed at enhancing spinal fusion outcomes [2][4] - Theradaptive has initiated a Series B investment round to support the expansion of its protein-engineering technology and the advancement of clinical studies related to OsteoAdapt [5][6] Company Overview - ATEC is focused on revolutionizing spine surgery through innovative solutions and has developed a procedural ecosystem that integrates informatics, imaging, navigation, and instrumentation [4][7] - Theradaptive is a clinical-stage regenerative medicine company that specializes in engineered protein therapeutics for various medical applications, including spine and orthopedic treatments [8] Technology and Market Potential - OsteoAdapt utilizes proprietary AMP2™ protein technology and is currently undergoing clinical trials, having received three FDA Breakthrough Device Designations, indicating its potential to meet significant medical needs in bone regeneration [3][6] - The U.S. spine surgery market exceeds $10 billion annually, with the biologics segment representing a $2+ billion opportunity, positioning OsteoAdapt as a transformative solution in the market [6]

Revenue Growth - Full-year 2025 total revenue increased by approximately 25% to around $764 million[2] - Surgical revenue for full-year 2025 grew by 26% to approximately $687 million, driven by a 24% increase in surgical volume[2] - The company expects full-year 2026 total revenue of $890 million, reflecting a growth of approximately 17% compared to 2025[7] - Full-year 2025 adjusted EBITDA guidance is reaffirmed at $91 million, indicating strong revenue growth leverage[3] Financial Performance - Adjusted EBITDA for full-year 2026 is anticipated to be around $130 million, contributing to an expected free cash flow of $20 million[7] - The company reported a cash balance of approximately $161 million as of December 31, 2025, with expected fourth-quarter free cash flow between $6 million and $8 million[3] Strategic Initiatives - The acquisition of exclusive U.S. distribution rights for Theradaptive's OsteoAdapt® is expected to enhance procedural offerings and address market concentration issues[6] - The company is positioned to shape the future of spine care with a scalable infrastructure and multiple growth catalysts ahead[4] Future Reporting - The company will report detailed financial results for Q4 and full-year 2025 on February 24, 2026[9] Operational Metrics - The company achieved an average revenue per surgical procedure growth of 2% in 2025[2]

Core Viewpoint - Alphatec Holdings, Inc. announced preliminary financial results for Q4 and full-year 2025, along with a financial outlook for full-year 2026 [1] Group 1: Preliminary Financial Results - For the fourth quarter ended December 31, 2025, Alphatec reported preliminary financial results [1] - The full-year results for 2025 were also disclosed, indicating the company's performance over the entire year [1] Group 2: Financial Outlook - The company provided a financial outlook for the full-year 2026, suggesting expectations for future performance [1]

Company Overview - Alphatec Holdings specializes in spinal surgery devices, offering a comprehensive portfolio that includes neural monitoring systems, spinal fixation platforms, interbody implants, biologics, and patient positioning solutions [6][7] - The company generates revenue primarily through the sale of proprietary medical devices and related products to hospitals and surgical centers, utilizing a direct sales force and independent distributors in the United States [6] - For the trailing twelve months (TTM), Alphatec reported revenue of $728.02 million and a net income of -$154.96 million, with a share price of $21.01 as of the latest report [4] Recent Transaction - CEO Miles Patrick executed an open-market sale of 100,000 shares for a total consideration of $2.1 million, which reflects a typical transaction size for his historical trading pattern [1][5] - Post-transaction, Patrick's direct holdings decreased by 6.82%, leaving him with 5.14 million shares valued at approximately $108.9 million [2][5] - The shares were sold at around $21.01 each, with the stock closing at $21.20 that day, indicating strong price momentum with a 126.3% increase over the past year [5][10] Operational Performance - Alphatec reported a revenue increase of 30% year over year in its most recent quarter, with surgical revenue climbing 31% to $177 million [10] - Adjusted EBITDA reached $26 million, expanding margins by over 800 basis points, and management raised full-year guidance to approximately $760 million in revenue and about $91 million in adjusted EBITDA [10] Insider Trading Context - The sale was executed under a prearranged Rule 10b5-1 plan, indicating it was a planned liquidity event rather than a directional shift in confidence [11] - Despite the sale, the CEO retains substantial direct and indirect holdings, maintaining alignment with shareholder interests [11]